Live News Categoriesequity

Beijing Luzhu Biotechnology Co., Ltd. (2480.HK) News

Follow Beijing Luzhu Biotechnology Co., Ltd. (2480.HK) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol 2480.HK Asset equity Sector Markets 90 days 1 Last 15 Updated Oct 12, 2026, 03:31 PM UTC Open live news feed

L BRIEF — Beijing Luzhu Biotechnology Says Recombinant RSV Vaccine Approved For Clinical Trials In China Oct 12 (Reuters) — Beijing Luzhu Biotechnology Co Ltd: Recombinant Rsv Vaccine Approved For Clinical Trials In China Further company coverage: 2480.HK (Reuters.Briefs@thomsonreuters.com;) GEOPOLITICS | Oct 12, 2026, 03:31 PM UTC